Why the study?
Do serum ANGPTL2 levels reflect clinical features of breast cancer progression and metastasis?
Population
Breast cancer patients, healthy subjects, and MDA-MB231 breast cancer cells/xenograft models
Authors
Loading...
Hypothesis-generating for ANGPTL2 as metastasis biomarker; prospective validation required before any clinical role.
Do serum ANGPTL2 levels reflect clinical features of breast cancer progression and metastasis?
Serum ANGPTL2 levels may serve as a potential biomarker for breast cancer metastasis and progression.
Endo et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: